Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avandamet (Rosiglitazone/Metformin) as First-Line Therapy in Type 2 Diabetes
NCT00499707Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of rosiglitazone, metformin in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Oct 2003; status: completed.
02
Drugs
rosiglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00499707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499707.